Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 513 participants.
Also called NCT02752412
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 513 participants
- Sponsor
- Registry
-
NCT02752412
-
- Other papers using this trial's data
- Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02752412. Randomized; no masking; primary purpose treatment. Start 2016-05-17 (actual); primary completion 2018-10-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
- Acronym
- LIXILAN JP-L
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine/Lixisenatide (HOE901/AVE0010)
- Intervention (Drug)
- Insulin glargine U100 (HOE901)
- Intervention (Drug)
- Metformin
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02752412- Content hash
9ab9dc31224e1fa36f4299689445ac809f6db357b66ab7595ec9506e0877cff0